Literature DB >> 27347890

Thyroid Hormone and Cardioprotection.

Anthony Martin Gerdes1, Kaie Ojamaa2,3.   

Abstract

The heart is a major target of thyroid hormones, with maintenance of euthyroid hormone balance critical for proper function. In particular, chronic low thyroid function can eventually lead to dilated heart failure with impaired coronary blood flow. New evidence also suggests that heart diseases trigger a reduction in cardiac tissue thyroid hormone levels, a condition that may not be detectible using serum hormone assays. Many animal and clinical studies have demonstrated a high prevalence of low thyroid function in heart diseases with worse outcomes from this condition. Animal and human studies have also demonstrated many benefits from thyroid hormone treatment of heart diseases, particularly heart failure. Nonetheless, this potential treatment has not yet translated to patients due to a number of important concerns. The most serious concern involves the potential of accidental overdose leading to increased arrhythmias and sudden death. Several important clinical studies, which actually used excessive doses of thyroid hormone analogs, have played a major role in convincing the medical community that thyroid hormones are simply too dangerous to be considered for treatment in cardiac patients. Nonetheless, this issue has not gone away due primarily to overwhelmingly positive evidence for treatment benefits and a new understanding of the cellular and molecular mechanisms underlying those benefits. This review will first discuss the clinical evidence for the use of thyroid hormones as a cardioprotective agent and then provide an overview of the cellular and molecular mechanisms underlying beneficial changes from thyroid hormone treatment of heart diseases. © 2016 American Physiological Society. Compr Physiol 6:1199-1219, 2016.
Copyright © 2016 John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27347890     DOI: 10.1002/cphy.c150012

Source DB:  PubMed          Journal:  Compr Physiol        ISSN: 2040-4603            Impact factor:   9.090


  12 in total

1.  Association Between Thyroid Dysfunction and Incidence of Atrial Fibrillation in Patients With Hypertrophic Obstructive Cardiomyopathy.

Authors:  Xiangbin Meng; Xu-Liang Wang; Zhi-Yuan Zhang; Kuo Zhang; Jun Gao; Ji-Lin Zheng; Jing-Jia Wang; Yu-Peng Liu; Jie Yang; Chen Li; Yi-Tian Zheng; Chunli Shao; Wen-Yao Wang; Yi-Da Tang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-04       Impact factor: 6.055

2.  Cardioprotective effect of thyroid hormone is mediated by AT2 receptor and involves nitric oxide production via Akt activation in mice.

Authors:  Ivson Bezerra da Silva; Dayane Aparecida Gomes; Natalia Alenina; Michael Bader; Robson Augusto Dos Santos; Maria Luiza M Barreto-Chaves
Journal:  Heart Vessels       Date:  2017-12-07       Impact factor: 2.037

3.  Comparison of Therapeutic Triiodothyronine Versus Metoprolol in the Treatment of Myocardial Infarction in Rats.

Authors:  Kuo Zhang; Yi-Da Tang; Youhua Zhang; Kaie Ojamaa; Ying Li; Amandeep Singh Saini; Maria Alicia Carrillo-Sepulveda; Viswanathan Rajagopalan; A Martin Gerdes
Journal:  Thyroid       Date:  2018-05-07       Impact factor: 6.568

4.  Modified Low-Dose Triiodo-L-thyronine Therapy Safely Improves Function Following Myocardial Ischemia-Reperfusion Injury.

Authors:  Viswanathan Rajagopalan; Youhua Zhang; Christine Pol; Clifford Costello; Samantha Seitter; Ann Lehto; Olga V Savinova; Yue-Feng Chen; A Martin Gerdes
Journal:  Front Physiol       Date:  2017-04-12       Impact factor: 4.566

5.  Adverse transverse-tubule remodeling in a rat model of heart failure is attenuated with low-dose triiodothyronine treatment.

Authors:  Shimin An; Nimra Gilani; Yuan Huang; Adam Muncan; Youhua Zhang; Yi-Da Tang; A Martin Gerdes; Kaie Ojamaa
Journal:  Mol Med       Date:  2019-12-06       Impact factor: 6.354

6.  Preoperative oral thyroid hormones to prevent euthyroid sick syndrome and attenuate myocardial ischemia-reperfusion injury after cardiac surgery with cardiopulmonary bypass in children: A randomized, double-blind, placebo-controlled trial.

Authors:  Jia-Qiang Zhang; Quan-Yong Yang; Fu-Shan Xue; Wei Zhang; Gui-Zhen Yang; Xu Liao; Fan-Min Meng
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

7.  Left ventricular phosphorylation patterns of Akt and ERK1/2 after triiodothyronine intracoronary perfusion in isolated hearts and short-term in vivo treatment in Wistar rats.

Authors:  José A Morales; Ruth M López; Jorge S López; Jair Lozano; Rosa A Jarillo; Héctor Flores; Enrique F Castillo
Journal:  Iran J Basic Med Sci       Date:  2020-08       Impact factor: 2.699

8.  Uridine phosphorylase 1 associates to biological and clinical significance in thyroid carcinoma cell lines.

Authors:  Yaoyao Guan; Adheesh Bhandari; Xiaohua Zhang; Ouchen Wang
Journal:  J Cell Mol Med       Date:  2019-09-09       Impact factor: 5.310

9.  Correlations between low thyroid function and incidence of atrial fibrillation in hypertrophic obstructive cardiomyopathy.

Authors:  Li-Min Liu; Li-Shui Shen; Shang-Yu Liu; Bin Tu; Guo-Liang Li; Feng Hu; Zhi-Cheng Hu; Ling-Min Wu; Xiao-Han Fan; Li-Hui Zheng; Li-Gang Ding; Yan Yao
Journal:  Chronic Dis Transl Med       Date:  2020-03-13

10.  Triiodothyronine maintains cardiac transverse-tubule structure and function.

Authors:  Nimra Gilani; Kaihao Wang; Adam Muncan; Jerrin Peter; Shimin An; Simran Bhatti; Khushbu Pandya; Youhua Zhang; Yi-Da Tang; A Martin Gerdes; Randy F Stout; Kaie Ojamaa
Journal:  J Mol Cell Cardiol       Date:  2021-06-24       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.